S-1/A: Salarius Pharmaceuticals and Decoy Therapeutics Announce Merger and $6.5 Million Public Offering Amidst Nasdaq Delisting Threat

Salarius Pharmaceuticals, facing delisting from Nasdaq and significant financial challenges, is proceeding with a merger with preclinical-stage Decoy Therapeutics and a public offering aiming to raise $6.5 million to fund the combined entity's operations and pipeline.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) is undergoing a two-step stock-for-stock merger with Decoy Therapeutics Inc., a preclinical-stage biotechnology company, with Decoy becoming a wholly-owned subsidiary of Salarius.
• The merger is conditioned on Salarius raising at least $6.0 million in a 'Qualified Financing' and maintaining its Nasdaq listing.
• Salarius is offering 10,794,765 shares of common stock or pre-funded warrants, along with Series A and Series B warrants, at an assumed combined public offering price of $0.7411 per share, aiming for approximately $6.5 million in net proceeds.
• Post-merger, Decoy stockholders are expected to own approximately 92.4% of the combined company, while Salarius legacy stockholders will retain about 7.6%, before accounting for the dilutive effects of the Qualified Financing.
• Salarius received a Nasdaq delisting notice on April 23, 2025, for failing to meet the $1.00 minimum bid price and $2.5 million stockholders' equity requirements, with extensions granted until mid-August 2025 for equity and late August 2025 for bid price.
• The proceeds from the offering are primarily allocated to advance the combined company's R&D programs ($1.5 million total for pan-Coronavirus, broad respiratory antiviral, colorectal cancer GPCR, and SP-3164 chemistry/exploratory antiviral work) and to pay off $590,000 of Decoy's outstanding promissory notes.
• Decoy's pipeline focuses on peptide conjugates for infectious diseases (pan-Coronavirus, broad respiratory antiviral) and oncology (colorectal cancer GPCR-targeted conjugate), leveraging its IMP3ACT platform (machine learning/AI-driven peptide design).
• Salarius' existing SP-2577 (seclidemstat) clinical trial for Ewing sarcoma was closed to conserve cash, but support continues for an investigator-initiated trial in myelodysplastic syndromes/chronic myelomonocytic leukemia, which had a partial clinical hold lifted in February 2025.
• Salarius' SP-3164, a targeted protein degrader, is planned to be integrated into Decoy's peptide-based proteolysis targeting chimeras (P-PROTACs) for metastatic colorectal cancer.
• Both Salarius and Decoy have incurred significant net losses since inception and have expressed 'substantial doubt' about their ability to continue as a going concern without additional funding.
• New investors in this offering will experience immediate and substantial dilution, with the pro forma as adjusted net tangible book value per share estimated at $0.28, representing a $0.46 dilution per share to new investors.
• The Series A and Series B warrants issued in the offering will only be exercisable upon receipt of shareholder approval, which Salarius has committed to seeking within 60 days of the offering's closing, and then every 40 days thereafter until obtained.
• The Preferred Stock (Series A and B) to be issued in the merger includes anti-dilution price protection for subsequent dilutive financings, which will reset the conversion ratio to provide additional shares to preferred stockholders.
• The combined company's management team will primarily consist of Decoy's senior management, with Frederick E. Pierce as CEO and Barbara Hibner as CSO, alongside Salarius' current CFO, Mark J. Rosenblum.

Sentiment

Score: 3

Explanation: The company is in a highly precarious financial and regulatory position, facing delisting and relying on a dilutive merger and offering to continue operations. While the merger brings a new pipeline, the risks are substantial, and the path to profitability is long and uncertain. The significant dilution and ongoing losses outweigh the potential benefits in the short to medium term.

Positives

• The merger with Decoy Therapeutics provides Salarius with a new, innovative preclinical pipeline focused on peptide conjugates and P-PROTACs, potentially expanding therapeutic opportunities in infectious diseases and oncology.
• The Qualified Financing is expected to raise approximately $6.5 million in net proceeds, which is crucial for the combined company's continued operations and R&D programs.
• Nasdaq granted extensions for Salarius to regain compliance with listing requirements (Equity Standard by mid-August 2025, Minimum Bid Price by late August 2025), providing a temporary reprieve.
• The partial clinical hold on the SP-2577 trial for myelodysplastic syndromes/chronic myelomonocytic leukemia was lifted in February 2025, allowing patient enrollment to resume.
• Decoy has a history of attracting significant non-dilutive funding from organizations like The Gates Foundation, BARDA, Google, and NVIDIA, which could continue to support future R&D efforts.
• The combined management team includes experienced executives from both Salarius and Decoy, with expertise in drug discovery, development, and financial management.

Negatives

• Both Salarius and Decoy have incurred significant net losses since inception and have expressed 'substantial doubt' about their ability to continue as a going concern.
• Salarius is currently non-compliant with Nasdaq's minimum bid price and stockholders' equity requirements and faces potential delisting if it fails to meet extended deadlines.
• The offering will result in 'immediate and substantial dilution' for new investors, with a dilution of $0.46 per share based on the assumed offering price.
• The Series A and Series B warrants issued in the offering are not immediately exercisable and require 'Shareholder Approval' to gain value, which is not guaranteed and will incur additional costs and management time.
• Salarius closed its Phase 1/2 clinical trial for SP-2577 in Ewing sarcoma to conserve cash, indicating severe financial constraints.
• Decoy's product candidates are all in the preclinical stage, meaning a long and uncertain path to potential commercialization and revenue generation.
• The anti-dilution provisions for the Preferred Stock could lead to further dilution for common stockholders if subsequent financings occur at lower prices.
• A significant portion of Decoy's liabilities consists of various convertible and promissory notes, totaling over $27 million in current liabilities as of March 31, 2025.

Risks

• The merger may be completed even if material adverse changes occur to Salarius or Decoy prior to closing, potentially reducing the value for stockholders.
• The combined company may never meet Nasdaq's initial listing standards, preventing the conversion of Preferred Stock into common stock and potentially leading to delisting.
• Stockholders may experience substantial additional dilution if Salarius continues selling newly issued shares through its existing equity line of credit (ELOC) or At-the-Market (ATM) agreement.
• The combined company will need to raise additional capital sooner than expected if cash reserves are lower than anticipated or if development costs increase, which may not be available on favorable terms or at all.
• The lack of a public market for Decoy's capital stock makes it difficult to evaluate its fair value, potentially leading to Salarius paying more than fair market value in the merger.
• The combined company may become involved in securities class action litigation, diverting management's attention and potentially exceeding insurance coverage.
• The Merger Agreement may be terminated, leading to substantial costs for Salarius and a negative impact on its stock price and future business.
• The market price of Salarius common stock may decline significantly after the merger due to negative investor reactions or failure to achieve anticipated benefits.
• Security holders of both companies will have a reduced ownership and voting interest in the combined company.
• There is no public market for the pre-funded warrants or common warrants being offered, limiting their liquidity.
• Holders of pre-funded warrants and common warrants will not have common stockholder rights until exercise.
• Salarius may not receive any additional funds upon the exercise of pre-funded warrants or Series B warrants due to cashless or zero-cash exercise options.
• Significant holders of warrants may be limited in their ability to exercise due to beneficial ownership limitations.
• If the merger is not completed, Salarius may be forced to cease operations, liquidate assets, and distribute any remaining cash to stockholders, which could result in significant losses for investors.
• The pendency of the merger could adversely affect Salarius' trading price and business relationships.
• Decoy's product candidates are all in the preclinical stage, with no guarantee of leading to marketable products or generating revenue.
• Decoy's reliance on third parties for clinical trials and manufacturing poses risks of delays, non-compliance, or unsatisfactory performance.
• The novel approach of Decoy's drug discovery platform (AI/ML-driven peptide conjugates) is unproven and may not lead to marketable products.
• Cybersecurity threats and other security disruptions could negatively impact the combined company's business and data integrity.
• The commercial success of Decoy's product candidates depends on acceptance by the medical community and payors, which is uncertain.
• Changes in the U.S. federal government's policies and regulations, particularly regarding healthcare spending and FDA processes, could adversely affect the combined company's business.

Future Outlook

The combined company aims to leverage Decoy's IMP3ACT platform to rapidly design, develop, and commercialize novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology. Key objectives include achieving clinical proof-of-concept for its lead pan-Coronavirus antiviral, advancing another transformative program to IND-enabling status within two years, and building platform manufacturing capabilities. The combined entity also intends to continue seeking non-dilutive funding and pursue value-enhancing partnerships. The legacy SP-2577 program will undergo a thorough review in mid-2025.

Management Comments

• Salarius' board of directors believed the merger was more favorable to its stockholders than a potential liquidation, which would likely occur if the merger is not consummated.
• Salarius' management believes its existing cash and cash equivalents, combined with the net proceeds from this offering and expected funds from The Gates Foundation, will be sufficient to fund operations through August 2026 if the merger closes.
• Decoy's management believes its IMP3ACT platform represents a fundamental revolution in peptide-conjugate drug discovery by substantially accelerating the time to design and validate new lead quality drug candidates.
• Decoy's management believes its approach will significantly decrease timelines, risk, and expense downstream in the therapeutic development process.
• Decoy's management believes its tripledemic antiviral program could represent the cornerstone of a significant global franchise.
• Decoy's management believes its strategy of being able to treat all three major respiratory viruses (Flu/COVID-19/RSV) with a single therapeutic will deliver a unique value proposition during seasonal surges of influenza-like illness.

Industry Context

The biopharmaceutical industry is characterized by rapid technological advancements, intense competition, and high capital requirements. The proposed merger aims to combine Salarius' existing small molecule assets with Decoy's novel peptide conjugate platform, positioning the combined entity in the emerging and high-growth field of peptide-based therapeutics, exemplified by recent successes in diabetes and weight loss treatments. The focus on infectious diseases and oncology aligns with areas of significant unmet medical need and substantial market opportunities. The use of AI/ML in drug discovery, as employed by Decoy, represents a cutting-edge trend in the industry, aiming to accelerate development and reduce costs. However, the industry also faces stringent regulatory hurdles, high failure rates in clinical trials, and increasing pressure for cost containment and pricing controls.

Comparison to Industry Standards

• Decoy's IMP3ACT platform aims to reduce drug discovery timelines from years to months or weeks, significantly faster than conventional drug development processes.
• Decoy's goal to achieve preclinical manufacturing readiness within significantly shorter timelines compared to traditional drug development processes, aiming to eventually meet or exceed the 100-day goal for vaccine manufacturing, is an ambitious target compared to industry norms.
• The expected low cost of goods (COGS) of less than $1/dose for Decoy's lead pan-Coronavirus inhibitor program, if achieved, would be highly competitive compared to many existing and developing therapeutics.
• Decoy's strategy of targeting multiple viral families (Coronaviruses, Influenza, Paramyxoviruses) with a single peptide conjugate antiviral is an innovative approach that contrasts with the more common single-target or single-family treatments in the antiviral space.
• The success of multi-targeting peptide conjugates, as demonstrated by drugs like Ozempic, Wegovy, Mounjaro, and ZepBound (Eli Lilly's blockbuster ZepBound demonstrates agonism of two different GPCRs), provides a benchmark for the potential of Decoy's polypharmacology approach.
• Decoy's use of human organoid and epithelial tissue models (e.g., Human Airway Epithelial (HAE) model) for preclinical testing is a modern approach to improve predictive power and reduce reliance on less translatable rodent models, aligning with advanced industry practices.
• The high failure rates in clinical trials (e.g., FDA indicating only 25%-30% of drugs proceed past Phase 3 to Phase 4) highlight the inherent risk Decoy faces, typical for early-stage biopharmaceutical companies.

Management Changes

Corporate Governance

Related Party Transactions

• Decoy officers/founders (Rick Pierce, Barbara Hibner, Peter Marschel) have outstanding non-interest bearing notes totaling approximately $140,000, which will remain outstanding and extend 12 months beyond the Merger Closing; proceeds from this offering will not be used to repay these notes.
• Rick Pierce (Decoy CEO) has an outstanding Demand Note (principal $55,555 plus accrued interest $9,817 as of March 31, 2025) which he has agreed to exchange for shares of Salarius Series B Preferred Stock.
• A family member of a Decoy officer/founder has an outstanding Demand Note (principal $83,333 plus accrued interest $15,625 as of March 31, 2025) and an outstanding Promissory Note (principal $100,000 plus accrued interest $10,566 as of March 31, 2025).
• Dr. William K. McVicar, a Salarius board member, serves as a consultant to DeuteRx, LLC and an affiliate, from which Salarius acquired its SP-3164 portfolio for $1.5 million and 5,000 shares of Salarius common stock, and agreed to future milestone and royalty payments.

Stakeholder Impact

• **Shareholders (Existing Salarius)**: Will experience significant dilution (from 100% to 7.6% pre-financing dilution) and face substantial uncertainty regarding the combined company's ability to maintain Nasdaq listing and achieve profitability. Their investment is at high risk.
• **Shareholders (Existing Decoy)**: Will gain access to a Nasdaq-listed company and potential public market liquidity, but their ownership will also be diluted by the Qualified Financing.
• **New Investors in Offering**: Will face immediate and substantial dilution, and the value of their investment is highly speculative given the combined company's early-stage pipeline and financial challenges.
• **Employees**: The merger will result in a new management structure, with Decoy's senior management taking key roles. Salarius has already reduced its workforce significantly, and the combined company's success will impact job security.
• **Creditors (Decoy)**: Certain promissory noteholders will exchange their debt for Series B Preferred Stock, while others will be paid off using offering proceeds, impacting their financial exposure and potential returns.
• **Customers/Patients**: The success of the combined company's drug development programs, particularly in infectious diseases and oncology, could lead to new therapeutic options for patients with high unmet medical needs, but this is a long-term, high-risk endeavor.

Next Steps

• Underwriters are expected to deliver the securities to purchasers on or about August __, 2025.
• The Merger Closing is expected to occur concurrently with the closing of this financing, assuming Salarius' continued listing on Nasdaq.
• Salarius intends to commence the Nasdaq initial listing process for the post-transaction entity following the consummation of this financing and the Merger Closing, once it expects to satisfy all applicable Nasdaq initial listing criteria.
• Salarius has agreed to call a special stockholder meeting to approve the conversion of the Preferred Stock into common stock, a new equity incentive plan, and a reverse stock split (if necessary), to be held as soon as practicable after the offering closes, but no later than 60 days, and then every 40 days thereafter until approval is obtained.
• The combined company intends to conduct a thorough review of the SP-2577 small molecule program in mid-2025.
• Decoy plans to file an Investigational New Drug (IND) application for its pan-Coronavirus fusion inhibitor program in the first half of 2026.
• Decoy aims to advance another transformative program to IND-enabling status within two years.
• The combined company plans to explore the use of SP-3164 as a building block in peptide-based PROTACs for metastatic colorectal cancer.
• Salarius intends to register the issuance of shares underlying the Preferred Stock within 60 days of the Merger Closing.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, evidenced by recurring losses, 'substantial doubt' about its ability to continue as a going concern, and active Nasdaq delisting proceedings. While the merger with Decoy Therapeutics and the associated public offering aim to provide a lifeline and a new preclinical pipeline, the risks are overwhelming. The offering itself is highly dilutive, immediately reducing the value for new investors. The combined entity's pipeline is early-stage, meaning commercialization and revenue generation are years away and highly uncertain. The continued Nasdaq listing is precarious, and failure to meet deadlines could lead to delisting, further eroding liquidity and investor confidence. Given the extreme financial fragility, high dilution, and significant operational and regulatory hurdles, the stock presents an exceptionally high-risk profile with a very low probability of near-term positive returns for investors. A seasoned investor would likely recommend divesting to avoid further capital erosion.

Keywords

Biotechnology, Pharmaceuticals, Merger, Public Offering, Warrants, Nasdaq Delisting, Preclinical Development, Peptide Conjugates, Targeted Protein Degradation, Oncology, Infectious Diseases, SP-3164, SP-2577, IMP3ACT Platform, Going Concern, Dilution, SEC Filing